Company performance
Add to research
Current Price
as of Mar 12, 2025$1.34
P/E Ratio
N/A
Market Cap
$303.65M
- CECE
Description
Add to research
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerGOSS
- Price$1.34+9.84%
Trading Information
- Market cap$303.65M
- Float80.36%
- Average Daily Volume (1m)1,701,122
- Average Daily Volume (3m)1,349,708
- EPS-$0.32
Company
- Revenue$105.32M
- Rev growth (1yr)N/A
- Net income-$30.80M
- Gross margin88.59%
- EBITDA margin-346.38%
- EBITDA-$32.84M
- EV$99.86M
- EV/Revenue0.95
- P/EN/A
- P/S2.88
- P/B5.61
- Debt/Equity376.14
Documents
Add to research
SEC Filings